Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
暂无分享,去创建一个
M. Maio | L. Mutti | D. Giannarelli | R. Danielli | E. Fonsatti | M. Altomonte | L. Calabrò | A. Morra | G. Amato | A. D. Di Giacomo | Ornella Cutaia
[1] I. Dick,et al. Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.
[2] M. Maio,et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme , 2013, Cancer Immunology, Immunotherapy.
[3] A. Hauschild,et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Berking,et al. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.
[5] J. Wolchok,et al. Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 , 2012 .
[6] J. Wolchok,et al. Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials , 2012 .
[7] A. Hauschild,et al. Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Hoogsteden,et al. New Roads Open Up for Implementing Immunotherapy in Mesothelioma , 2012, Clinical & developmental immunology.
[9] J. Neal,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] G. Ceresoli,et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. , 2012, Lung cancer.
[11] J. Kirkwood,et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Chasalow,et al. Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.
[13] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[14] M. Maio,et al. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. , 2010, Seminars in oncology.
[15] J. Wolchok,et al. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. , 2010, Seminars in oncology.
[16] A. Korman,et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. , 2010, Seminars in oncology.
[17] A. Ribas. Clinical development of the anti-CTLA-4 antibody tremelimumab. , 2010, Seminars in oncology.
[18] M. Maio,et al. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. , 2010, Seminars in oncology.
[19] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[20] P. LoRusso,et al. Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells , 2010, Clinical Cancer Research.
[21] J. Wolchok,et al. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.
[22] G. Ceresoli,et al. Second-line treatment for malignant pleural mesothelioma. , 2010, Cancer treatment reviews.
[23] M. Grégoire. What's the place of immunotherapy in malignant mesothelioma treatments? , 2010, Cell adhesion & migration.
[24] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[25] R. Ramlau,et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] C. Gridelli,et al. Multidisciplinary treatment of malignant pleural mesothelioma. , 2007, The oncologist.
[27] B. Robinson,et al. Advances in malignant mesothelioma. , 2005, The New England journal of medicine.
[28] M. Byrne,et al. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Tsao. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study , 2012 .
[31] A. Cattelan,et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). , 1999, Journal of immunotherapy.
[32] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.